Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals’ siRNA Drug Delivery Platform …

Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals’ siRNA Drug Delivery Platform …
Arrowhead Research Corporation (NASDAQ:ARWR) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week. An article published on May 24, entitled “Minute invaders that aid the body”, reports on the revolutionary potential of gene silencing and the pioneering role of the siRNA delivery system developed by Arrowhead majority-owned subsidiary …

Read more on SYS-CON Media

Arrowhead Adds Noble Prize Winner To Advisory Board

Arrowhead Adds Noble Prize Winner To Advisory Board
Pasadena-based Arrowhead Research Corporation announced today that it has added Nobel Prize winner Dr. Lee Hartwell to its Scientific Advisory Board. Hartwell, President of the Fred Hutchinson Cancer Research Center, received the Nobel Prize in Medicine in 2001. According to Arrowhead, Hartwell will help the firm focus its strategy and extend its scientific reach. Arrowhead is commercializing …

Read more on socalTech.com

Arrowhead Adds Noble Prize Winner To Advisory Board

Arrowhead Adds Noble Prize Winner To Advisory Board
Pasadena-based Arrowhead Research Corporation announced today that it has added Nobel Prize winner Dr. Lee Hartwell to its Scientific Advisory Board. Hartwell, President of the Fred Hutchinson Cancer Research Center, received the Nobel Prize in Medicine in 2001. According to Arrowhead, Hartwell will help the firm focus its strategy and extend its scientific reach. Arrowhead is commercializing …

Read more on socalTech.com

Arrowhead Adds Nobel Prize Winner To Advisory Board

Arrowhead Adds Nobel Prize Winner To Advisory Board
Pasadena-based Arrowhead Research Corporation announced today that it has added Nobel Prize winner Dr. Lee Hartwell to its Scientific Advisory Board. Hartwell, President of the Fred Hutchinson Cancer Research Center, received the Nobel Prize in Medicine in 2001. According to Arrowhead, Hartwell will help the firm focus its strategy and extend its scientific reach. Arrowhead is commercializing …

Read more on socalTech.com

Arrowhead seeks to regain Nasdaq compliance

Arrowhead seeks to regain Nasdaq compliance
PASADENA – Arrowhead Research Corp., a nanotechnology company that commercializes new technologies, has received another 180-day grace period to regain compliance with Nasdaq Capital Market’s $1 minimum bid requirement.

Read more on Whittier Daily News

Next Page »